Reviewer disclosures

ReviewerEmploymentResearch grantOther research supportSpeakers’ bureau/ honorariaExpert witnessOwnership interestConsultant/advisory boardOther
Alan B. ChaitUniversity of WashingtonNoneNoneNoneNoneNoneNoneNone
Ira J. GoldbergColumbia UniversityNoneNoneNoneNoneNoneNoneNone
Scott D. GrundyUT Southwestern Medical CenterNoneNoneNoneNoneNoneNoneNone
Rodica Pop-BusuiUniversity of MichiganNHLBI; NIDDKFormerly Amylin Pharmaceuticals, now BMS*NoneNoneNoneT1D Exchange Scientific Review Committee*None
Henry RodriguezUniversity of South Florida College of MedicineBristol-Myers Squibb; Daiichi Sankyo; Novo NordiskNoneNoneNoneNoneRoche Diagnostics*Merck* (Member of Data Safety Monitoring Board)
Debra L. SimmonsUniversity of Utah and Salt Lake City VAMCNoneNoneNoneNoneNoneNoneNone
Joseph WolfsdorfBoston Children’s HospitalNoneNoneNoneNoneNoneNoneNone
  • This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.